Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Olopatadine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 3/20 | 0.98 |
| ▸ | LMNA | P02545 | 1/20 | 0.98 |
| ▸ | PARP1 | P09874 | 1/20 | 0.77 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
| ▸ | RECQL | P46063 | 1/20 | 0.67 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.67 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Olopatadine SCHEMBL122589 | 1.00 | HRH1 (0.98) | HRH1LMNAPARP1KDM4EALDH1A1 | |
| Olopatadine SCHEMBL29402772 | 1.00 | HRH1 (0.98) | HRH1LMNAPARP1KDM4EALDH1A1 | |
| Olopatadine SCHEMBL29381853 | 1.00 | HRH1 (0.98) | HRH1LMNAPARP1KDM4EALDH1A1 | |
| Olopatadine SCHEMBL28322959 | 1.00 | HRH1 (0.98) | HRH1LMNAPARP1KDM4EALDH1A1 | |
| Olopatadine SCHEMBL5324205 | 1.00 | HRH1 (0.98) | HRH1LMNAPARP1KDM4EALDH1A1 | |
| Olopatadine SCHEMBL23213 | 1.00 | HRH1 (0.98) | HRH1LMNAPARP1KDM4EALDH1A1 | |
| Olopatadine SCHEMBL693865 | 0.99 | HRH1 (0.96) | HRH1LMNAPARP1KDM4EALDH1A1 | |
| Olopatadine SCHEMBL693866 | 0.99 | HRH1 (0.96) | HRH1LMNAPARP1KDM4EALDH1A1 | |
| Olopatadine SCHEMBL4669 | 0.99 | HRH1 (1.00) | HRH1LMNAPARP1ALDH1A1KCNH2 | |
| Olopatadine SCHEMBL29517420 | 0.99 | HRH1 (1.00) | HRH1LMNAPARP1ALDH1A1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240058355-A1 | TREATMENTS OF OCULAR ALLERGY WITH ALCAFTADINE | JOHNSON & JOHNSON VISION CARE, INC. | 2024-02-22 | — | — | US | disclosed |
| US-20230285504-A1 | INHIBITION OF REPERFUSION INJURY WITH A PSD-95 INHIBITOR | NONO INC. (CA) | 2023-09-14 | — | — | US | disclosed |
| US-20230181594-A1 | TREATMENTS OF OCULAR ALLERGY WITH ALCAFTADINE | JOHNSON & JOHNSON VISION CARE (US) | 2023-06-15 | — | — | US | disclosed |
| US-20210030762-A1 | TREATMENTS OF OCULAR ALLERGY WITH ALCAFTADINE | JOHNSON & JOHNSON VISION CARE, INC. | 2021-02-04 | — | — | US | disclosed |
| EP-3682895-A1 | CO-ADMINISTRATION OF AN AGENT LINKED TO A TAT-INTERNALIZATION PEPTIDE WITH A MAST CELL DEGRANULATION INHIBITOR | NoNO Inc. (CA) | 2020-07-22 | — | — | EP | disclosed |
| US-10617695-B2 | Ophthalmic compositions containing alcaftadine | VISTAKON PHARMACEUTICALS, LLC (US) | 2020-04-14 | — | — | US | disclosed |
| EP-3150209-B1 | OCULAR ALLERGY TREATMENTS | VISTAKON PHARMACEUTICALS LLC (US) | 2019-07-24 | — | — | EP | disclosed |
| EP-3150209-A1 | OCULAR ALLERGY TREATMENTS | Vistakon Pharmaceuticals, LLC (US) | 2017-04-05 | — | — | EP | disclosed |
| US-20170065605-A1 | TREATMENTS OF OCULAR ALLERGY WITH ALCAFTADINE | VISTAKON PHARMACEUTICALS, LLC | 2017-03-09 | — | — | US | disclosed |
| EP-2004196-B1 | OCULAR ALLERGY TREATMENTS | VISTAKON PHARMACEUTICALS LLC (US) | 2016-06-29 | — | — | EP | disclosed |
| US-8664215-B2 | Ocular allergy treatments with alcaftadine | VISTAKON PHARMACEUTICALS, LLC (US) | 2014-03-04 | — | — | US | disclosed |
| CN-102967665-A | Content measuring method for olopatadine hydrochloride eye drops | JIANGSU JIBEIER PHARMACEUTICAL CO LTD | 2013-03-13 | — | — | CN | disclosed |
| US-20120094978-A1 | Ocular Allergy Treatments | PARASRAMPURIA JAGDISH (US) | 2012-04-19 | — | — | US | disclosed |
| EP-2004196-A2 | OCULAR ALLERGY TREATMENTS | Vistakon Pharmaceuticals, LLC (US) | 2008-12-24 | — | — | EP | disclosed |
| US-20080051385-A1 | OCULAR ALLERGY TREATMENTS | JOHNSON & JOHNSON VISION CARE, INC. | 2008-02-28 | — | — | US | disclosed |
| WO-2007117971-A2 | OCULAR ALLERGY TREATMENTS | VISTAKON PHARMACEUTICALS, LLC (US) | 2007-10-18 | — | — | WO | disclosed |
| WO-2007105234-A2 | A PROCESS FOR THE PREPARATION OF ISOMERS OF 11-[3-(DIMETHYLAMINO)PROPYLIDENE]-6, 11-DIHYDRODIBENZ [b, e] OXEPIN-2-ACETIC ACID HYDROCHLORIDE AND POLYMORPHS THEREOF | USV LIMITED (IN) | 2007-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230181594-A1 | TREATMENTS OF OCULAR ALLERGY WITH ALCAFTADINE | CCL11, HRH2, IL5 | HRH1 7/4885LMNA 4550/4885PARP1 3472/4885 |
| US-20240058355-A1 | TREATMENTS OF OCULAR ALLERGY WITH ALCAFTADINE | CCL11, HRH2, IL5 | HRH1 7/4885LMNA 4550/4885PARP1 3472/4885 |
| US-20170065605-A1 | TREATMENTS OF OCULAR ALLERGY WITH ALCAFTADINE | CCL11, HRH2, IL5 | HRH1 7/4885LMNA 4550/4885PARP1 3472/4885 |
| US-20080051385-A1 | OCULAR ALLERGY TREATMENTS | HRH2, CMA1, TPSAB1 | HRH1 9/4885LMNA 4274/4885PARP1 3447/4885 |
| US-20210030762-A1 | TREATMENTS OF OCULAR ALLERGY WITH ALCAFTADINE | CCL11, HRH2, IL5 | HRH1 7/4885LMNA 4550/4885PARP1 3472/4885 |
| US-20120094978-A1 | Ocular Allergy Treatments | HRH2, CMA1, TPSAB1 | HRH1 9/4885LMNA 4274/4885PARP1 3447/4885 |
| US-10617695-B2 | Ophthalmic compositions containing alcaftadine | CCL11, PDE6H, ADRB1 | HRH1 31/4885LMNA 3843/4885PARP1 3659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.